Logo image of PTRA

PROTERRA INC (PTRA) Stock Fundamental Analysis

NASDAQ:PTRA - Nasdaq - US74374T1097 - Common Stock - Currency: USD

0.067  -0.02 (-25.56%)

After market: 0.065 0 (-2.99%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PTRA. PTRA was compared to 128 industry peers in the Machinery industry. PTRA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PTRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PTRA has reported negative net income.
In the past year PTRA has reported a negative cash flow from operations.
PTRA Yearly Net Income VS EBIT VS OCF VS FCFPTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -100M -200M -300M

1.2 Ratios

The profitability ratios for PTRA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTRA Yearly ROA, ROE, ROICPTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PTRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTRA Yearly Profit, Operating, Gross MarginsPTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -20 -40 -60 -80 -100

More info and screens

2

2. Health

2.1 Basic Checks

PTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTRA has more shares outstanding than it did 1 year ago.
PTRA has a worse debt/assets ratio than last year.
PTRA Yearly Shares OutstandingPTRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 50M 100M 150M 200M
PTRA Yearly Total Debt VS Total AssetsPTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.67, we must say that PTRA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.67, PTRA is not doing good in the industry: 90.63% of the companies in the same industry are doing better.
PTRA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PTRA has a better Debt to Equity ratio (0.00) than 85.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.67
ROIC/WACCN/A
WACC6.89%
PTRA Yearly LT Debt VS Equity VS FCFPTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.39 indicates that PTRA should not have too much problems paying its short term obligations.
PTRA's Current ratio of 1.39 is on the low side compared to the rest of the industry. PTRA is outperformed by 82.03% of its industry peers.
PTRA has a Quick Ratio of 1.39. This is a bad value and indicates that PTRA is not financially healthy enough and could expect problems in meeting its short term obligations.
PTRA has a worse Quick ratio (0.76) than 81.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.76
PTRA Yearly Current Assets VS Current LiabilitesPTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PTRA have decreased strongly by -194.37% in the last year.
PTRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.59%.
EPS 1Y (TTM)-194.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.04%
Revenue 1Y (TTM)29.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.95%

3.2 Future

The Earnings Per Share is expected to grow by 20.03% on average over the next years. This is a very strong growth
PTRA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.82% yearly.
EPS Next Y-20.84%
EPS Next 2Y29.75%
EPS Next 3Y25.51%
EPS Next 5Y20.03%
Revenue Next Year47.51%
Revenue Next 2Y52.46%
Revenue Next 3Y59.79%
Revenue Next 5Y46.82%

3.3 Evolution

PTRA Yearly Revenue VS EstimatesPTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
PTRA Yearly EPS VS EstimatesPTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTRA. In the last year negative earnings were reported.
Also next year PTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTRA Price Earnings VS Forward Price EarningsPTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTRA Per share dataPTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as PTRA's earnings are expected to grow with 25.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25.51%

More info and screens

0

5. Dividend

5.1 Amount

PTRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTERRA INC

NASDAQ:PTRA (8/16/2023, 8:17:12 PM)

After market: 0.065 0 (-2.99%)

0.067

-0.02 (-25.56%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)08-09 2023-08-09/amc
Earnings (Next)N/A N/A
Inst Owners0.16%
Inst Owner Change0%
Ins Owners60.57%
Ins Owner Change0%
Market Cap15.26M
Analysts78.33
Price Target3.73 (5467.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-295.67%
Min EPS beat(2)-295.67%
Max EPS beat(2)-295.67%
EPS beat(4)0
Avg EPS beat(4)-166.66%
Min EPS beat(4)-295.67%
Max EPS beat(4)-98.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-10.08%
Min Revenue beat(2)-10.19%
Max Revenue beat(2)-9.97%
Revenue beat(4)1
Avg Revenue beat(4)-3.32%
Min Revenue beat(4)-10.19%
Max Revenue beat(4)16.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-88.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS1.5
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 265.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.76
Altman-Z -2.67
F-Score3
WACC6.89%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.04%
EPS Next Y-20.84%
EPS Next 2Y29.75%
EPS Next 3Y25.51%
EPS Next 5Y20.03%
Revenue 1Y (TTM)29.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.95%
Revenue Next Year47.51%
Revenue Next 2Y52.46%
Revenue Next 3Y59.79%
Revenue Next 5Y46.82%
EBIT growth 1Y-59.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.14%
EBIT Next 3Y35.23%
EBIT Next 5Y26.57%
FCF growth 1Y-137.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.92%
OCF growth 3YN/A
OCF growth 5YN/A